This book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL). Careful attention is devoted to the emerging individually tailored treatment strategies, including checkpoint inhibition, that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The new edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by key opinion leaders to reflect recent progressin the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.

Part I: Epidemiology and Pathogenesis

Epidemiology of Hodgkin Lymphoma
The role of viruses in the genesis of Hodgkin Lymphoma
Pathology and molecular pathology of Hodgkin Lymphoma
Microenvironment, cross-talk and immune escape mechanisms.-What will we learn from Genomics and Proteomics in Hodgkin Lymphoma?
Part II: Diagnosis and first-line treatment
Clinical evaluation
Functional imaging in Hodgkin Lymphoma
Prognostic factors. - Principles of Radiation Therapy for Hodgkin Lymphoma
Principles of chemotherapy in Hodgkin Lymphoma
Treatment of early favorable Hodgkin Lymphoma
Treatment of early unfavorable Hodgkin Lymphoma
Treatment of advanced-stage Hodgkin Lymphoma
Optimizing Decision Making in HL.- Part III: Special clinical situations
Paediatric/adolescent Hodgkin Lymphoma
The management of elderly patients with Hodgkin Lymphoma
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
The management of Hodgkin Lymphoma during pregnancy
The management of HIV-Hodgkin Lymphoma
Part IV: Relapsed and refractory disease
Relapsed and refractory Hodgkin Lymphoma
Allogeneic transplantation for relapsed Hodgkin Lymphoma
Targeting CD30 in Patients with Hodgkin Lymphoma
Hodgkin Lymphoma and PD-1 blockade
Other new agents for Hodgkin Lymphoma
Part V: Survivorship
Quality of Life in Hodgkin lymphoma
Second malignancy risk after treatment of Hodgkin Lymphoma
Cardiovascular and pulmonary late effects
Gonadal dysfunction and fertility preservation in Hodgkin Lymphoma patients
Fatigue.